How drug pricing, tariffs, and manufacturing decisions are becoming connected.
For years, pharmaceutical companies could treat U.S. reimbursement, European market access, trade policy and manufacturing strategy as related but mostly separate issues. That separation is becoming harder to defend.
The Administration has linked U.S. drug prices to prices paid abroad, pursued voluntary most favored nation agreements, proposed international benchmarks in Medicare, and tied pharmaceutical tariff treatment to both pricing and domestic manufacturing commitments. The important change is not simply that the United States wants lower drug prices.
Foreign reimbursement systems and manufacturing choices are now being pulled into U.S. trade policy. The Supreme Court held in February 2026 that IEEPA does not authorize the President to impose tariffs.
The Administration responded by preserving and expanding other statutory tools. Section 232 is being used against patented pharmaceutical imports and Section 301 is being used to examine foreign pharmaceutical pricing practices.
FDA is also using the Commissioner's National Priority Voucher (CNPV) program to connect regulatory timing with priorities that include domestic manufacturing and supply chain resilience.
The United Kingdom shows the negotiated path. Germany shows the enforcement path.1-6,13
Management should ask more than “What does this reimbursement rule require?” The better question is “How does this pricing, launch, manufacturing or market access decision change our exposure under U.S. payment policy and trade law?”
The old line between reimbursement policy and corporate strategy is fading. The change is easy to describe. A pricing concession in one country can affect an international benchmark.
A launch delay can change which country becomes a reference point. A manufacturing location can change tariff exposure or government leverage.
A market access decision that once looked local can now affect U.S. revenue assumptions. Consider a simple example in which a manufacturer launches a drug in Europe at a lower negotiated price.
That price could later become relevant to a U.S. international benchmark. The same company may manufacture the drug outside the United States, creating a separate tariff question.
Two decisions made by different teams can now affect the economics of the same product. This does not mean every European price automatically becomes a U.S. price or every foreign reimbursement decision becomes a trade violation. The rules differ by program, product and country.
Some U.S. models remain proposed, and the Germany investigation has not produced a final finding. The direction is nevertheless clear: U.S. policymakers are using international price comparisons, company agreements, and trade authorities to influence pharmaceutical economics at home and abroad.
Therefore, management cannot leave drug pricing only to market access, trade only to customs counsel, manufacturing only to operations, or government affairs only to monitoring. Senior leaders need one view of how a decision in one part of the company can move value or risk somewhere else.
The strategic advantage is understanding what a price or manufacturing decision in one market can do to the rest of the company.
The Supreme Court narrowed one tariff pathway. The Administration then turned more heavily to laws that specifically authorize trade action. [Primary source anchors: Supreme Court,1 White House,2 USTR.3]
On February 20, 2026, the Supreme Court held in Learning Resources, Inc. v. Trump, together with Trump v. V.O.S. Selections, Inc., that IEEPA does not authorize the President to impose tariffs. The Court’s ruling matters because it rejected the use of a broad emergency economic statute as tariff authority.
It did not hold that the President lacks all tariff authority. Congress has separately delegated trade powers through other statutes.1
The Administration made its response explicit. On the day of the decision, the White House ended the IEEPA tariff actions at issue while stating that duties imposed under Section 232 of the Trade Expansion Act and Section 301 of the Trade Act were not affected.
USTR separately announced that it would initiate several accelerated Section 301 investigations and specifically identified pharmaceutical pricing practices as a target area.2,3
Section 122 served as a temporary bridge through a 150-day import surcharge tied to balance of payments concerns, but pharmaceuticals and pharmaceutical ingredients were exempt. The more durable pharmaceutical story is the Administration’s move toward Sections 232 and 301.2
Section 232 focuses on the product: where it comes from and whether imports threaten national security. On April 2, 2026, the President used it to impose a 100% baseline tariff on covered patented pharmaceuticals and associated ingredients, with different rates for trade deal countries and preferential treatment for companies with approved U.S. manufacturing plans or MFN pricing agreements.
The proclamation links tariff treatment, MFN pricing and domestic manufacturing. Section 301 focuses on the foreign government: whether its acts, policies or practices may be unreasonable, discriminatory or burdensome to U.S. commerce.
On June 18, USTR used that authority to open the Germany pharmaceutical pricing investigation.4,5 The legal novelty is not that Sections 232 and 301 are new statutes.
Both have long histories and established procedures. What has not yet been squarely tested by the Supreme Court is this coordinated post Learning Resources use of statute specific trade authorities to recreate leverage that had previously been asserted through IEEPA, especially when pharmaceutical pricing, reimbursement, market access, and onshoring are treated as parts of one trade strategy.
That does not mean the architecture is unlawful. It means companies should treat litigation risk and statutory fit as part of the strategic analysis rather than assume the new scheme has already received judicial approval.
The post IEEPA strategy is not simply “more tariffs.” Section 232 pressures products, manufacturing, and supply chains through a national security theory. Section 301 pressures foreign government practices through an unfair trade theory. Used together, they create leverage on both the company and the country. The statutes are established. Their coordinated pharmaceutical use in this form is still developing.
Trade policy is not the only way the federal government is influencing pharmaceutical manufacturing decisions. FDA is also using regulatory incentives that may change how management evaluates the economics of producing medicines in the United States.13
The CNPV program is designed to accelerate review of selected drugs and biologics that advance defined U.S. health priorities. Those priorities include domestic manufacturing and supply chain resilience, affordability, unmet medical need and important medical innovation.
FDA describes a target review timeline of one to two months for selected applications, compared with six months or more under other priority review programs.13 For management teams, the important point is the value of time.
A U.S. manufacturing decision has traditionally been evaluated against construction costs, labor, taxes, supply chain reliability, and access to the U.S. market. Regulatory timing can now become another part of that calculation.
A company considering U.S. manufacturing should therefore ask whether the location of manufacturing could affect more than tariff exposure and supply chain risk. If a product can qualify for CNPV review, faster regulatory timing may also affect launch planning, revenue timing and the value of the asset. FDA lists multiple approvals under the program in 2026.13
A company should not move manufacturing simply to pursue a voucher. CNPV eligibility depends on the product and the program criteria, and manufacturing investments remain long term decisions. The program does give CEOs and boards another variable to consider when comparing U.S. manufacturing with alternatives elsewhere.
For companies already evaluating U.S. manufacturing capacity, regulatory timing belongs in the same discussion as construction costs, labor, taxes, tariff treatment and supply chain resilience. CNPV does not change the need for a sound manufacturing business case. It gives management another factor to consider when comparing U.S. manufacturing with alternatives elsewhere.13
There is not a single MFN program, as the Administration is using several different approaches that connect prices paid abroad with U.S. pricing policy. The current MFN approach began with Executive Orders in April and May 2025 directing federal agencies to lower prescription drug prices and pursue prices for Americans that more closely reflect prices available in comparable developed countries.10
Since then, the White House says it has announced 17 MFN agreements with major pharmaceutical manufacturers. Those agreements, TrumpRx and related pricing initiatives show that the Administration is using several tools at once: negotiation, public pressure, federal payment policy, market access programs and trade leverage.7,11
GLOBE is a proposed mandatory CMS Innovation Center model for certain Medicare Part B drugs. As proposed, manufacturers would owe rebates when U.S. prices exceed an international benchmark.
CMS currently anticipates an October 1, 2026, start, subject to a final rule.8 One point is especially important. GLOBE would not simply stack a lower international price on top of an IRA negotiated price.
The proposal would exclude a Part B drug while an IRA Maximum Fair Price, or MFP, is in effect. The challenge is therefore managing different pricing systems at different points in a product’s life, not choosing the lower of two federal prices.8
GUARD is a proposed mandatory CMS Innovation Center model for certain Medicare Part D drugs. If finalized, CMS anticipates a January 1, 2027, start. Like GLOBE, GUARD would use rebates tied to prices paid in economically comparable countries.9
GUARD would also exclude a drug while an MFP is in effect. International pricing can still affect U.S. economics before or after that period, so management needs to know which program applies when and how an earlier pricing decision may affect the product later.9
GENEROUS works differently—it is a voluntary Medicaid model launched in January 2026. Participating manufacturers provide supplemental rebates intended to align Medicaid net prices with what selected other countries pay, while participating states use standardized coverage rules.12
For executives, the acronym is not the important part. The larger point is that international price comparisons are becoming more common inside U.S. healthcare policy while trade policy is simultaneously being used to pressure foreign pricing and manufacturing behavior. Payment and trade are now moving on parallel tracks.
Do not treat GLOBE, GUARD, and GENEROUS as one unified “MFN rule.” They work differently, apply to different populations and are at different stages. The C-suite needs a product-by-product map, not one slogan.
The UK shows how reimbursement policy and tariff policy can be negotiated together [Primary source anchor: UK Government].6
The U.S. and UK pharmaceutical arrangement is one of the clearest examples of reimbursement, MFN policy and trade law being negotiated together. Under the arrangement published April 2, 2026, the UK committed to increase the net NHS price paid for prospective new medicines by 25% beginning in April 2026, increase spending on new medicines over time, modify NICE access economics and cap specified VPAG repayment rates.6
In return, the United States committed to protect qualifying UK pharmaceutical products from Section 232 tariffs through January 19, 2029, provided specified company MFN and tariff agreement conditions are met, and to refrain from additional Section 301 pharmaceutical tariffs during the stated period. The arrangement also expressly references GENEROUS and anticipated GLOBE and GUARD protections intended to reduce launch disincentives in a lower priced market.6
The significance is straightforward. The arrangement does not treat drug prices, patient access, supply chain resilience, MFN, Section 232 and Section 301 as separate policy files. It puts them in the same bargain. That is the architecture this analysis is describing.
The UK arrangement is the negotiated version of the new framework: price and access commitments on one side, tariff and launch protections on the other. For global manufacturers, market access and trade strategy need to be managed together.
Germany shows how the same policy shift can reach a foreign reimbursement system. [Primary source anchor: USTR].5
On June 18, 2026, USTR opened a Section 301 investigation into Germany’s alleged “persistent underpayment” for innovative pharmaceutical products. In simple terms, USTR is asking whether German pricing and reimbursement practices are unreasonable or discriminatory and burden or restrict U.S. commerce.
Those are allegations being investigated, not final legal findings.5 The investigation is still underway.
Written comments were due August 10, 2026, and USTR has scheduled a public hearing for September 22, 2026. The process can end without tariffs, through findings and responsive action, or through a negotiated resolution.5
The larger point goes beyond Germany. Section 232 can pressure where and how pharmaceutical companies manufacture. S
ection 301 can pressure how foreign governments pay for medicines. Germany therefore supplies the second half of the coordinated strategy that the April Section 232 proclamation began to make concrete.4,5
Do not assume the Germany investigation means tariffs are inevitable. Section 301 is a process. Management should assume, however, that foreign pharmaceutical pricing policy can now lead to U.S. trade scrutiny, political pressure, and, potentially, responsive action.
The objective is to turn policy complexity into decision discipline.
The goal is simple: give management one way to see how pricing, trade, manufacturing and market access decisions connect. Management does not need to predict every final rule.
It needs a repeatable way to test major decisions against a changing set of legal and commercial risks. We recommend building one cross border pricing and trade exposure map around the company's major products and pipeline assets.
This same framework should be used in acquisitions, licensing deals and major capital projects. A product's pricing history, European launch sequence, manufacturing footprint and government commitments can affect future value even when they do not stand out in a traditional healthcare regulatory review. Investors and boards should ask whether those factors add value, limit flexibility or create a risk that has not been modeled.
The current environment favors preparation over prediction. Build one enterprise exposure map. Do not maintain separate U.S., UK, and EU trade analyses that never connect. Put the major products, markets, prices, rebates, launch dates and manufacturing locations on one decision map.
Revisit launch sequencing assumptions. Identify lower priced markets that could affect an international benchmark or a government negotiating position. Consider whether timing, sequencing, or a different contract structure changes the economics.
Stress test the UK and Germany scenarios. Ask what the company would do if a key market were offered a UK style accommodation, faced a Germany style Section 301 investigation, or saw its pharmaceutical exports subjected to Section 232 leverage.
Review the manufacturing footprint through a trade and regulatory lens. For each critical patented product and ingredient, identify country of origin, applicable Section 232 treatment, domestic manufacturing commitments, trade deal status, alternative sourcing and the financial cost of a tariff or policy change.
For products tied to current or planned U.S. manufacturing, assess whether CNPV eligibility or regulatory timing should be part of the investment analysis.13
Set a senior escalation rule. Major pricing, launch and manufacturing decisions should trigger a cross functional review before the company gives up flexibility that may be valuable in another market. Monitor the rules that can change the map.
GLOBE and GUARD remain proposed, the Germany Section 301 process is ongoing, and the pharmaceutical Section 232 regime contains country and company specific conditions. Management should plan around the current landscape while keeping enough flexibility to update assumptions as rules, agreements, enforcement actions, and litigation evolve.
Can management explain, on one page, how a major pricing decision in Europe could change U.S. reimbursement, trade, manufacturing and valuation exposure? If not, the company probably does not yet have one enterprise view of the risk.
Drug pricing has entered a new phase. Foreign pharmaceutical prices are now part of more than a domestic affordability debate.
International prices appear in federal payment models and manufacturer agreements, while pharmaceutical pricing, manufacturing and market access have become subjects of bilateral trade negotiation and statutory trade enforcement.
The Supreme Court’s Learning Resources decision removed IEEPA as the tariff authority the Administration had been using. The policy response was not retreat.
The White House expressly preserved Sections 232 and 301, USTR announced new Section 301 investigations that included pharmaceutical pricing, the President imposed a pharmaceutical Section 232 regime in April, and USTR opened the Germany pharmaceutical pricing investigation in June.1-5
For CEOs, CFOs, general counsel and commercial leaders, the most important development may be the structure that emerges from those actions. Section 232 can link tariff treatment to manufacturing, domestic investment and MFN commitments.
Section 301 can convert a foreign reimbursement policy into a U.S. trade dispute. CNPV adds regulatory timing to the manufacturing decision by making domestic manufacturing and supply chain resilience relevant to accelerated review eligibility for selected products.
Together, these tools can affect company decisions, government policy and the economics of where a product is developed, manufactured and launched.13
The statutes themselves are not new, and this paper does not assume that a court would uphold or invalidate every future application. The unresolved issue is how far this coordinated use of Sections 232 and 301 can go when tested against the language, procedures and limits of Sections 232 and 301.
Companies should not wait for that litigation to be resolved before understanding their exposure. The better approach is to see the connections before the commercial decision is made. That is where policy foresight becomes business strategy.
About the Author
Ron Lanton, Senior Partner & Global Strategist at
References
The following primary government sources support the principal legal and policy developments discussed in this paper. They are included so readers can independently verify the underlying events. All were current as of August 14, 2026.
